Key Insights On The Central Nervous System Biomarkers Market 2023 – Size, Driver, And Major Players
The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032
As per The Business Research Company’s Central Nervous System Biomarkers Global Market Report 2023, the central nervous system biomarkers market is expected to show significant growth in the forecast period.
Key insights from the central nervous system biomarkers market forecast include:
- Market Size
The global central nervous system biomarkers market is expected to grow from $4.51 billion in 2022 to $5.01 billion in 2023 at a compound annual growth rate (CAGR) of 11.0%. The central nervous system biomarkers market is expected to reach $7.3 billion in 2027 at a CAGR of 9.9%.
- Major Driver
The rise in neurological illnesses is expected to propel the growth of the central nervous system biomarker market going forward. For instance, in May 2020, according to the Centers for Disease Control and Prevention, a US-based government agency, Alzheimer’s disease affected an estimated 5.8 million Americans aged 65 and older. This number is expected to nearly triple to 14 million by 2060. Moreover, the number of people living with the disease doubles every five years after age 65. Therefore, the rise in neurological illnesses drives the growth of the central nervous system biomarker market.
View More On The Central Nervous System Biomarkers Market Report 2023 – https://www.thebusinessresearchcompany.com/report/central-nervous-system-biomarkers-global-market-report
- Key Trend
Innovative drug approvals are a key trend gaining popularity in the central nervous system biomarker market. Major companies operating in the central nervous system biomarkers market are focused on developing innovative drugs and getting approval to strengthen their position in the market. For instance, in January 2022, Denovo Biopharma LLC, a US-based clinical-stage biopharmaceutical company, announced the US Food and Drug Administration’s (FDA) approval and authorization of the company’s investigational new drug (IND) application of DB104 (liafensine) for the treatment of treatment-resistant depression (TRD). It is the first biomarker-guided global CNS clinical trial for TRD. Additionally, it could help identify patients who are more likely to respond to liafensine, which could lead to more personalized treatment decisions. Liafensine is a novel compound that works by increasing levels of dopamine and norepinephrine in the brain.
- Largest Region
North America was the largest region in the central nervous system biomarkers market in 2022.
- Major Players
Major players in the central nervous system biomarkers market are F. Hoffmann-La Roche AG, Novartis AG, Siemens Healthineers, Thermo Fisher Scientific Inc, Abbott Laboratories, Merck KGaA, Eurofins Scientific, Charles River Laboratories International Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Axon Neuroscience SE, Alector Inc., Oryzon Genomics S.A., Abastar Mdx Inc., Banyan Biomarkers Inc., Avacta Group PLC, Geno Technology Inc., Anavex Life Sciences Corp., Alseres Pharmaceuticals Inc., Aposense Ltd., Applied Neurosolutions Inc., C2N Diagnostics, Alzheon Inc., DiaGenic ASA, Abiant Inc., Avid Radiopharmaceuticals Inc. , Acumen Pharmaceuticals Inc. , Cassava Sciences Inc., and Denali Therapeutics.
Request A Sample Of The Global Central Nervous System Biomarkers Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=12632&type=smp
Key Central Nervous System Biomarkers Market Segments
The global central nervous system biomarkers market is segmented –
1) By Type: Safety Biomarker, Efficacy Biomarker, Validation Biomarker, Other Types
2) By Disease: Multiple Sclerosis, Alzheimer’s Disease, Parkinson’s Disease, Traumatic Brain Injury, Other Diseases
3) By Application: Drug Discovery And Development, Personalized Medicines, Disease Risk Assessment, Diagnostics, Other Applications
4) By End-Users: Diagnostic Labs, Clinics, Hospitals, Research Centers, Other End-Users
The Central Nervous System Biomarkers Global Market Report 2023 provides an in-depth analysis on the central nervous system biomarkers market size, trends and drivers, opportunities, strategies, and companies analysis. The countries covered in the central nervous system biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.
View More Related Reports –
Central Lab Global Market Report 2023
Generic Central Nervous System Drugs Global Market Report 2023
Biomarkers Global Market Report 2023
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
